The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InBaxter International (BAX) reported a significant net loss in Q4, with adjusted earnings per share (EPS) of $0.44, falling short of analysts' estimates of $0.54. This earnings miss occurred despite a notable 8% increase in worldwide net sales, reaching $2.97 billion. Adding to investor concerns, the medical products company provided a weak fiscal year 2026 outlook. It projected adjusted EPS for FY26 to be between $1.85 and $2.05, considerably below the Street's expectation of $2.25 per share. Following these announcements, Baxter's stock (BAX) experienced a sharp decline, tumbling 14.63% in pre-market trading. The disappointing Q4 results and subdued long-term guidance signal significant negative market sentiment for the company.